Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1-infected individuals
Protocol Number:
J1331
Phase:
Pilot
Physician:
Richard Ambinder
Purpose:
To determine the fraction of patients who maintain antiretroviral therapy (ART), through day 60 of allogeneic hematopoietic stem cell transplant(alloHSCT).
Eligibility:
HIV-1-infected individuals who plan to undergo a myeloablative or non- myeloablative bone marrow transplant
Treatment:
This is a one arm single institution study. HIV-1 infected patients undergoing alloHSCT are eligible. A multidisciplinary team will select an optimal ART regimen and every effort will be made to maintain this oral ART regimen through day 60 day post-alloHSCT. In addition, the subcutaneous antiretroviral, enfuvirtide, will be added during any periods when oral medications are unlikely to be tolerated due to nausea (e.g. during administration of high dose cyclophosphamide) or cannot be tolerated for other reasons (e.g. mucositis).
Population:
Adult
Last Update
04/17/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer